Bavarian Nordic A/S: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Bavarian Nordic A/S Presents New Data from Phase II Study of PROSTVAC-Reuters
Reuters reported that Bavarian Nordic A/S has presented a number of new data from phase II study of prostate cancer vaccine PROSTVAC at the annual cancer conference of American Society of Clinical Oncology (ASCO) in Chicago, the United States. The preliminary analysis suggests that the combination of PROSTVAC and Sm-153 (Quadramet) in patients with metastatic castration-resistant prostate cancer (mCRPC) is well tolerated with similar toxicity profile to the Sm-153 alone.
Latest Developments for Bavarian Nordic A/S
Latest Key Developments in Pharmaceuticals
- Merck & Co Inc announces FDA approves RAGWITEK Sublingual tablet as immunotherapy to treat short ragweed Pollen-Induced Allergic Rhinitis with or without conjunctivitis in adults
- GlaxoSmithKline Plc and Genmab A/S receive FDA approval for Arzerra(r) (ofatumumab) as first-line treatment in combination with Chlorambucil for Patients with Chronic Lymphocytic Leukemia
- OPKO acquires dry powder inhaler to treat respiratory disorders
- American Capital receives $210 mln from sale of SPL Acquisition Corp to Shenzhen Hepalink Pharmaceutical Co., Ltd
- Share this
- Digg this